Application 090314
- Type
- ANDA
- Sponsor
- MYLAN ASI
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | SUMATRIPTAN SUCCINATE | SUMATRIPTAN SUCCINATE | INJECTABLE;SUBCUTANEOUS | EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | No | No |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A090314-001 | SUMATRIPTAN SUCCINATE | SUMATRIPTAN SUCCINATE | EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | SOLUTION / SUBCUTANEOUS | 2010-06-10 | ||
| A090314-002 | SUMATRIPTAN SUCCINATE (AUTOINJECTOR) | SUMATRIPTAN SUCCINATE | EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | SOLUTION / SUBCUTANEOUS | AB | 2026-01-30 |
Therapeutic equivalence codes#
| Application-product | TE code |
|---|---|
| A090314-002 | AB |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2023-05-13 08:27 UTC | 2023-05 | A090314-001 | SUMATRIPTAN SUCCINATE | EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | INJECTABLE / SUBCUTANEOUS | 2010-06-10 | 053a50430f4f… | ||
| 2023-01-26 05:58 UTC | 2023-01 | A090314-001 | SUMATRIPTAN SUCCINATE | EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | INJECTABLE / SUBCUTANEOUS | 2010-06-10 | 3bdfa0b2c4d7… | ||
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | A090314-001 | SUMATRIPTAN SUCCINATE | EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | INJECTABLE / SUBCUTANEOUS | 2010-06-10 | 3a93d1ddd44b… | ||
| 2022-10-28 04:53 UTC | 2022-10 | A090314-001 | SUMATRIPTAN SUCCINATE | EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | INJECTABLE / SUBCUTANEOUS | 2010-06-10 | f41ea6bd6efb… | ||
| 2022-09-29 23:25 UTC | 2022-09 | A090314-001 | SUMATRIPTAN SUCCINATE | EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | INJECTABLE / SUBCUTANEOUS | 2010-06-10 | e64feba35796… | ||
| 2022-07-09 03:26 UTC · 3 captures of this ZIP | 2022-07 | A090314-001 | SUMATRIPTAN SUCCINATE | EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | INJECTABLE / SUBCUTANEOUS | 2010-06-10 | cb3db0bc1861… | ||
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A090314-001 | SUMATRIPTAN SUCCINATE | EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | INJECTABLE / SUBCUTANEOUS | 2010-06-10 | a50c72e98297… | ||
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A090314-002 | SUMATRIPTAN SUCCINATE (AUTOINJECTOR) | EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | INJECTABLE / SUBCUTANEOUS | AB | 2026-01-30 | a50c72e98297… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-10-15 13:18:30 | 2026-09 | A090314-002 | AB | 1 | c2088c7a36db… |
| 2026-09-14 22:38:34 | 2026-08 | A090314-002 | AB | 1 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | A090314-002 | AB | 1 | caaa826d4ba7… |
| 2019-12-13 00:20 UTC | 2019-12 | A090314-001 | AP | 1 | 74a2ff9319b5… |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A090314-001 | AP | 1 | 87673890dc5c… |
| 2021-03-12 10:30 UTC | 2021-03 | A090314-001 | AP | 1 | 5aa47cf7b7d7… |
| 2020-12-22 03:56 UTC | 2020-12 | A090314-001 | AP | 1 | 8869cabd3fbd… |
| 2020-11-12 02:37 UTC | 2020-11 | A090314-001 | AP | 1 | c0c555d07b60… |
| 2019-12-14 00:12 UTC | 2019-12 | A090314-001 | AP | 1 | 3f01610625f2… |
| 2019-09-15 20:21 UTC | 2019-09 | A090314-001 | AP | 1 | b00525d2431f… |
| 2019-07-19 19:46 UTC | 2019-07 | A090314-001 | AP | 1 | ea99ee380514… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A090314-002 | AB | 1 | a50c72e98297… |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| SUMATRIPTAN | SUMATRIPTAN | Golden State Medical Supply, Inc. | 4b4915d3-be7a-e5fa-e063-6294a90a7f98 | 2026-04-23 | Warnings, Adverse reactions | 090314 ANDA090314 |
| SUMATRIPTAN | SUMATRIPTAN | Strides Pharma Science Limited | 1909558d-8342-4af0-9487-eecdaac70070 | 2026-04-15 | Warnings, Adverse reactions | 090314 ANDA090314 |
| sumatriptan | SUMATRIPTAN | ONESOURCE SPECIALTY PHARMA LIMITED | 587e6bb5-a665-4396-814e-ce893a20290b | 2026-02-20 | Warnings, Adverse reactions | 090314 ANDA090314 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
NDC Listings For This Application#
| NDC | Name | Nonproprietary name | Labeler | Marketing category | Status |
|---|---|---|---|---|---|
| 25021-703 | sumatriptan | sumatriptan | Sagent Pharmaceuticals | ANDA | Current |
| 67457-879 | sumatriptan | sumatriptan | Mylan Institutional LLC | ANDA | Current |
| 67457-879 | sumatriptan | sumatriptan | Mylan Institutional LLC | ANDA | Current |
| 67457-879 | sumatriptan | sumatriptan | Mylan Institutional LLC | ANDA | Current |